Cigna price target lowered to $355 from $377 at RBC Capital

RBC Capital analyst Ben Hendrix lowered the firm’s price target on Cigna (CI) to $355 from $377 and keeps an Outperform rating on the shares after its Q4 earnings miss and below-consensus FY25 guide. The firm was “disappointed” to see elevated specialty drug costs and inpatient acuity drive a higher-than-expected MCR – Medical Care Ratio – outlook for 2025, and while overall trend fell in line with management’s expectations across the risk-based business, acuity shift weighed heavily on the stop-loss book, the analyst tells investors in a research note.